Accepted for/Published in: JMIR Research Protocols
Date Submitted: Jan 7, 2022
Date Accepted: Apr 25, 2022
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Developing Reporting Guidelines for Studies of HIV Drug Resistance Prevalence: Protocol of a Mixed-methods Study
ABSTRACT
Background:
HIV drug resistance is a global health problem which limits the effectiveness of antiretroviral therapy (ART). Adequate surveillance of HIV drug resistance is challenged by heterogenous and inadequate data reporting, which compromises the accuracy, interpretation, and usability of prevalence estimates. Previous research has found that the quality of reporting in studies of HIV drug resistance prevalence is low, and thus better guidance is needed to ensure complete and uniform reporting.
Objective:
This paper aims to develop reporting guidelines for studies of HIV drug resistance by achieving consensus among experts on what items should be reported in these studies.
Methods:
We will conduct a sequential explanatory mixed methods study among authors and users of studies of HIV drug resistance. The two-phase design will include a cross-sectional electronic survey (quantitative phase) followed by a focus group discussion (qualitative phase). Survey participants will rate the essentiality of various reporting items, which will be analyzed in a validity ratio to determine the items that will be retained for further evaluation. Retained items will form a list of potential reporting items that will be reviewed in a focus group discussion informed by grounded theory to produce a finalized set of reporting items.
Results:
This study received ethics approval from the Hamilton Integrated Research Ethics Board (project number #11558) on November 11, 2020. As of March 2021, 46 participants provided informed consent and completed the electronic survey. In October 2021 nine of these participants participated in virtual focus group discussions.
Conclusions:
This study will provide a reporting checklist for studies of HIV drug resistance by achieving consensus among experts on what items should be reported in these studies. The results of this work will be refined and elaborated on by a writing committee of HIV drug resistance experts and external reviewers to develop finalized reporting guidelines.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.